BioLife Solutions, Inc. (BLFS)
$
21.66
+0.12 (0.55%)
Key metrics
Financial statements
Free cash flow per share
0.2395
Market cap
1 Billion
Price to sales ratio
12.9719
Debt to equity
0.0764
Current ratio
4.7300
Income quality
-0.6101
Average inventory
28.3 Million
ROE
-0.0309
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services tailored for the cell and gene therapy industry across the United States, Canada, Europe, the Middle East, Africa, and beyond. The company plays a crucial role in basic and applied research and the commercial manufacturing of biologic-based therapies. Recently, the company reported a net loss of -$20,184,000.00 indicating challenges in its operations. The operating income ratio stands at -0.09 providing insight into the company's operational profitability margin. Among its offerings are proprietary biopreservation media products, such as HypoThermosol FRS and CryoStor, specifically formulated to mitigate preservation-induced, delayed-onset cell damage and death. Additionally, the ThawSTAR line features automated vial and cryobag thawing products designed to control the temperature and timing of the thawing process. The company also supplies evo shipping containers, which are cloud-connected passive storage and transport solutions for temperature-sensitive biologics and pharmaceuticals, along with liquid nitrogen laboratory freezers, cryogenic equipment, and related accessories, as well as biological and pharmaceutical storage services. Furthermore, the company reported depreciation and amortization expenses of $8,661,000.00 reflecting the wear and tear of its assets, with total costs and expenses amounting to $89,383,000.00 highlighting its overall spending. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington, and its stock is identified with the symbol 'BLFS' in the market. The stock is currently affordable at $21.66 making it suitable for budget-conscious investors. With a market capitalization of $1,030,175,592.00 the company is classified as a small-cap player in the market. Notably, the stock has a low average trading volume of 625,004.00 indicating lower market activity. BioLife Solutions is recognized as a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. As it belongs to the Healthcare sector, the company continues to drive innovation and growth, enhancing its position as a competitive force within its field.
Is BioLife Solutions, Inc. (BLFS) a good investment?
Investing in BioLife Solutions, Inc. (BLFS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is BioLife Solutions, Inc. (BLFS)'s stock forecast?
Analysts predict BioLife Solutions, Inc. stock to fluctuate between $18.70 (low) and $29.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is BioLife Solutions, Inc.'s market capitalization?
As of 2025-07-01, BioLife Solutions, Inc.'s market cap is $1,030,175,592, based on 47,561,200 outstanding shares.
How does BioLife Solutions, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., BioLife Solutions, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy BioLife Solutions, Inc. (BLFS) stock?
To buy BioLife Solutions, Inc. (BLFS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BLFS. Place an order (Market, Limit, etc.).
What is the best time to invest in BioLife Solutions, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has BioLife Solutions, Inc. stock ever split?
BioLife Solutions, Inc.'s last stock split was 1:14 on 2014-01-29.
How did BioLife Solutions, Inc. perform in the last earnings report?
Revenue: $82,254,000 | EPS: -$0.44 | Growth: -71.05%.
Where can I find BioLife Solutions, Inc.'s investor relations reports?
Visit https://www.biolifesolutions.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for BioLife Solutions, Inc.?
You can explore historical data from here
What is the all-time high and low for BioLife Solutions, Inc. stock?
All-time high: $60.67 (2021-09-01) | All-time low: $8.92 (2023-10-30).
What are the key trends affecting BioLife Solutions, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
seekingalpha.com
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by.
prnewswire.com
BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET.
seekingalpha.com
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers.
zacks.com
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being.
prnewswire.com
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven.
zacks.com
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago.
See all news
